Franklin Genomic Advancements ETF
HELX
8 hedge funds and large institutions have $964K invested in Franklin Genomic Advancements ETF in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.36% less ownership
Funds ownership: 31.48% → 30.12% (-1.4%)
17% less capital invested
Capital invested by funds: $1.16M → $964K (-$200K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$246K |
| 2 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$1.95K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$990 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$227K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$70.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$24.7K |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $460K | +$246K | +7,462 | +108% |
|
|
2
Commonwealth Equity Services
Waltham,
Massachusetts
| $271K | -$70.7K | -2,143 | -20% |
|
|
BFEC
3
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $151K | +$1.95K | +59 | +1% |
|
|
4
UBS Group
Zurich,
Switzerland
| $40K | -$24.7K | -749 | -38% |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $33K | – | – | – |
|
|
HI
6
Harbour Investments
Madison,
Wisconsin
| $6K | +$6.2K | +188 | New |
|
|
GWM
7
Geneos Wealth Management
Englewood,
Colorado
| $2K | – | – | – |
|
|
8
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1K | +$990 | +30 | New |
|
|
APA
9
American Portfolios Advisors
Holbrook,
New York
| – | -$227K | -6,135 | Closed |
|
|
SWM
10
Spire Wealth Management
Mclean,
Virginia
| – | -$3K | -75 | Closed |
|
HELX Hedge Fund Activity: Q2 2022 in Review
8 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2022, worth a combined $964K — down 17% from $1.16M a quarter earlier.
Fund positioning in HELX was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, adding an estimated $246K. The largest seller was American Portfolios Advisors, exiting entirely with an estimated $227K sold.
- 8 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $964K of Franklin Genomic Advancements ETF stock for Q2 2022, down 17% quarter-over-quarter.
- 2 funds opened new Franklin Genomic Advancements ETF positions in Q2 2022 and 2 closed out, a net change of 0 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q2 2022 was Jane Street, an estimated $246K added.
- The largest Franklin Genomic Advancements ETF seller in Q2 2022 was American Portfolios Advisors, an estimated $227K sold.
Based on aggregated 13F filings for Q2 2022.